XYMOGEN has over a quarter century of experience in providing quality professional supplements to healthcare practitioners. As an independent health sciences company, XYMOGEN has introduced numerous innovations to the Functional Medicine community. XYMOGEN’s place as the fastest-growing company and brand in the practitioner-channel was reinforced in 2007, 2008, 2010 and 2011 when it was recognized by Inc. Magazine as one of the Inc. 5000 fastest-growing, private companies in America.
New exciting growth initiatives:
- Completion of a state-of-the-art 136,000 sq. ft. Manufacturing Facility / Laboratory
- Aggressive International Expansion - XYMOGEN® formulas are now available in Canada, one of the largest international markets. By the second half of 2012 XYMOGEN® formulas will also be available in Australia, another one of the largest international markets, among others.
- Prescription Food Initiative employing a patented and 2010 FDA Accepted NDI [New Dietary Ingredient]
- Quarterly Pipeline Launches - XYMOGEN® maintains its status as the most innovative Practitioner-Channel company with a minimum 10 new formulas per quarter
Investment Philosophy is based upon the strategy outlined in the following steps:
- We grew consistently and as predicted - XYMOGEN® sales have grown 32 consecutive quarters since our launch in October-2003.
- Investors were kept informed - We have created this online Investor site to keep investors informed. This site will be updated on a quarterly basis to keep Investors informed of our progress and the current value of XYMOGEN® Shares. The current valuation, as of December 31, 2011, is $56.51 per share. Shares are re-valued at the end of each quarter and post on or about the 15th of the following month; i.e., January 15, April 15, July 15 and October 15.
- New investors were cultivated by us and by other investors - XYMOGEN® will continually maintain information about the advantages an investment in XYMOGEN® represents.
- There were no surprises, disappointments or unkept promises - We have met or exceeded most all of our sales projections. Capital raised through this Offering will likely propel XYMOGEN® to unprecedented growth as we expand regionally and bring to market our Medical Board of Advisors’ “Pipeline of Formulas”.
- We always raised money well in advance of need - This, coupled with our $3 Million Line-of-Credit, provides XYMOGEN® the capital to accomplish our current pace of $50 Million in revenue for 2012.
- We had luck - We are fortunate to be in the Practitioner-Channel of the Health & Wellness Sector. Over the past five years, this has been amongst the fastest growing business sectors in our country. At a time when few companies are growing, as of December 31, 2011, XYMOGEN® has grown revenues for 32 consecutive quarters.
XYMOGEN® has generated sustained growth for 32 consecutive quarters and has realized over 500% Growth in the past 5 years. Over this 5-year period the Share price has grown from $15 to $56.51. We believe with the aforementioned initiatives the next five years will likely be our best growth period to date.
Even Better News. XYMOGEN® Share price is valued quarterly and, as of December 31, 2011, the Share Price is posted at $56.51.
